For combination therapy, the FDA recommends 200 mg of penpulimab-kcqx every 3 weeks. Monotherapy is recommended at 200 mg ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic ...

On April 23, 2025, the U.S. Food and Drug Administration (FDA) granted approval to Akeso Biopharma Co., Ltd.’s penpulimab-kcqx for the first-line treatment of adults with recurrent or metastatic ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

编者按：2025年美国临床肿瘤学会年会（ASCO）将于美国东部时间（GMT-5）5月30日至6月3日在芝加哥召开。本次会议聚焦肿瘤治疗前沿，将呈现化疗、内分泌治疗、免疫治疗、靶向治疗及精准医学的最新进展。日前，官网已经公布各项研究摘要，本文特将消化领 ...

GUM disease is a widespread condition primarily caused by the build-up of plaque, leading to inflamed gums. Common symptoms ...

Daiichi Sankyo seeks Japanese approval for Enhertu to treat patients with HER2 positive metastatic solid tumours: Tokyo Friday, April 25, 2025, 09:00 Hrs [IST] Daiichi Sankyo has ...

Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.

Sex workers are the new gays (as they were pre-2000s)—a sexual minority that the masses often misconstrue, misunderstand, ...